Coronary artery bypass grafting following in-stent restenosis of drug-eluting stents deployed in the left main coronary artery

Circulation Journal

Volumn 72, Issue 3, 2008, Pages 502-504

  Kanemitsu, Shinji ^a   Tanaka, Keizo ^a   Tanaka, Jin ^a   Suzuki, Hitoshi ^a   Kinoshita, Toshihiko ^a  

^a ANJO KOSEI HOSPITAL   (Japan)

Author keywords

Coronary artery bypass graft; Drug eluting stent; Restenosis

Indexed keywords

AGED; ANGIOCARDIOGRAPHY; ARTICLE; BLOOD TRANSFUSION; CASE REPORT; CLINICAL FEATURE; CORONARY ARTERY BYPASS GRAFT; DISEASE COURSE; DRUG ELUTING STENT; EMERGENCY SURGERY; FEMALE; GRAFT PATENCY; HOSPITAL ADMISSION; HUMAN; IN-STENT RESTENOSIS; LEFT CORONARY ARTERY; MALE; OFF PUMP CORONARY SURGERY; POSTOPERATIVE HEMORRHAGE; POSTOPERATIVE PERIOD; TRANSLUMINAL CORONARY ANGIOPLASTY; UNSTABLE ANGINA PECTORIS;

AGED; CORONARY ANGIOGRAPHY; CORONARY ARTERY BYPASS; CORONARY RESTENOSIS; CORONARY VESSELS; DRUG-ELUTING STENTS; FEMALE; HUMANS; MALE;

EID: 42649095178     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.72.502     Document Type: Article

References (10)

1. Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT, et al. One year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS stent: The TAXUS IV trial. Circulation 2004; 109: 1942-1947.
2. Williams DO, Holubkov R, Yeh W, Bourassa MG, Al-Bassam M, Block PC, et al. Percutaneous coronary interventions in the current era compared with 1985-1986: The National Heart, Lung, and Blood Institute registries. Circulation 2000; 102: 2945-2951.
3. Lee MS, Kapoor N, Jamal F, Czer L, Aragon J, Forrester J, et al. Comparison of coronary artery bypass surgery with percutaneous coronary intervention with drug-eluting stents for unprotected left main coronary artery disease. J Am Coll Cardiol 2006; 47: 864-870.
4. Al Suwaidi J, Yeh W, Cohen HA, Detre KM, Williams DO, Holmes Jr DR. Immediate and one-year outcome in patients with coronary bifurcation lesions in the modern era (NHLBI dynamic registry). Am J Cardiol 2001; 87: 1139-1144.
5. Tanabe K, Hoye A, Lemos PA, Aoki J, Arampatzis CA, Saia F, et al. Restenosis rates following bifurcation stenting with sirolimus-eluting stents for de novo narrowings. Am J Cardiol 2004; 94: 115-118.
6. Colombo A, Stankovic G, Orlic D, Corvaja N, Liistro F, Airoldi F, et al. Modified T-stenting technique with crushing for bifurcation lesions immediate results and 30-day outcome. Catheter Cardiovasc Interv 2003; 60: 145-151.
7. Kuzniar J, Splawinska B, Malinga K, Mazurek AP, Splawinski J. Pharmacodynamics of ticlopidine: Relation between dose and time of administration to platelet inhibition. Int J Clin Pharmacol Ther 1996; 34: 357-361.
8. Silber S, Albertsson P, Avilés FF, Camici PG, Colombo A, Hamm C, et al. Guidelines for percutaneous coronary interventions: The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Eur Heart J 2005; 26: 804-847.
9. Kapetanakis EI, Medlam DA, Petro KR, Haile E, Hill PC, Dullum MK et al. Effect of clopidogrel premedication in off-pump cardiac surgery: Are we forfeiting the benefits of reduced hemorrhagic sequelae? Circulation 2006; 113: 1667-1674.
10. Lindvall G, Sartipy U, van der Linden J. Aprotinin reduces bleeding and blood product use in patients treated with clopidogrel before coronary artery bypass grafting. Ann Thorac Surg 2005; 80: 922-927.